AN2 Therapeutics (ANTX) Operating Income (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Operating Income for 6 consecutive years, with -$10.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income rose 8.55% year-over-year to -$10.6 million; the TTM figure through Mar 2026 stood at -$37.1 million (up 25.8% YoY), while the FY2025 annual figure was -$38.1 million, up 32.89% from the prior year.
• Operating Income retreated to -$10.6 million in Q1 2026 per ANTX's latest filing, from -$9.3 million in the prior quarter.
• Across five years, Operating Income topped out at -$7.2 million in Q2 2025 and bottomed at -$18.8 million in Q4 2023.
• Historically, Operating Income has averaged -$12.8 million across 5 years, with a median of -$11.8 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Income plunged 274.78% — and 2025, when it surged 54.56%.
• AN2 Therapeutics' Operating Income stood at -$12.5 million in 2022, then sank by 50.81% to -$18.8 million in 2023, then surged by 54.3% to -$8.6 million in 2024, then fell by 8.35% to -$9.3 million in 2025, then decreased by 13.26% to -$10.6 million in 2026.
• Business Quant data shows ANTX's Operating Income at -$10.6 million in Q1 2026, -$9.3 million in Q4 2025, and -$10.0 million in Q3 2025.